US/UK/Canada

Share

About Us

BrainCool AB (publ) is an innovative medical device company that develops, markets, and sells leading medical cooling systems for indications and areas with significant medical benefits within the healthcare sector. The company focuses on two business segments, Brain Cooling and Pain Management. BrainCool AB (publ) is based in Lund, Sweden, and its share is listed on AktieTorget.

Contacts

  • Martin Waleij

    CEO


    Medicon Village, Scheelevägen 2, 223 81 Lund
    +46733937076
    http://www.braincool.se

    • Links

    Pick a time period -
    Tags ( Active)

    BioStock Investor Meeting: BrainCool

    BrainCool presented at BioStock Investor Meeting, September 20. The event took place in Stockholm, featuring several exciting life science companies presenting their business cases to investors and potential partners.See the presentation via: BioStock Investor Meeting September 2023 | BrainCool - YouTube  See the interview via:  BioStock Investor Meeting | Interview with BrainCool | September 2023 - YouTube  This is a press release from BioStock - Connecting Innovation & Capital. https://

    BioStock: BrainCool received patent approval in the EU

    BrainCool has completed the final step in securing patent protection for its BrainCool System. The European Union has approved the technology for managing shivering during medical cooling, marking a milestone for BrainCool. This approval adds to the existing patents granted in the United States, Sweden, Japan, South Korea and China.Read the article at biostock.se: https://www.biostock.se/en/2023/07/braincool-received-patent-approval-in-the-eu/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

    BioStock: Financing agreement secures capacity increase in BrainCool

    Recently, BrainCool entered into an exclusive distribution and partnership agreement with American ZOLL. The agreement included an initial order worth at least  100 million SEK. To secure the resources for the start of production of ZOLL's orders, the company also signed a financing agreement of up to 20 million SEK with two of BrainCool's major owners. BioStock contacted CEO Martin Waleij for a comment.Read the full interview with Martin Waleij at biostock.se: https://www.biostock.se/en/2023/06/financing-agreement-secures-capacity-increase-in-braincool/ This is a press release from

    BioStock: BrainCool’s CEO on the agreement with ZOLL

    BrainCool has entered into a distribution agreement with US-based ZOLL, one of the world’s largest manufacturers and distributors of medical devices. The agreement covers the company’s IQool System for the treatment of neurological fever. BrainCool’s CEO Martin Waleij visited BioStock’s studio to talk about the deal, worth more than SEK 100 million.Watch Martin Waleij present BrainCool and talk about the agreement with ZOLL att biostock.se: https://www.biostock.se/en/2023/05/braincools-ceo-on-the-agreement-with-zoll/ This is a press release from BioStock - Connecting Innovation &

    BioStock: BrainCool’s CEO on the purchase agreement in the US

    BrainCool has signed a purchase agreement for IQool System with Vanderbilt Health in the US. The aim is to make the medical device available in the 74 hospitals that are part of that health system. BioStock talked to BrainCool’s CEO Martin Waleij about the agreement and its potential commercial benefits.Read the full interview with Martin Waleij at biostock.se: https://www.biostock.se/en/2023/05/braincools-ceo-on-the-purchase-agreement-in-the-us/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

    BioStock: BrainCool comments on the cancer project in the US

    With market approval and a breakthrough stamp in the US, BrainCool is approaching the commercial phase with Cooral System. CEO Martin Waleij tells BioStock that in parallel with possible fast track reimbursement processes, a clinical study will also be conducted in the U.S. to secure higher revenues in the long term. In addition, he sees opportunities for the studies, which the company is planning in collaboration with Medicare, to be financed through research grants. Alternatively that Medicare will provide compensation for patient recruitment in the study.Read the full interview with

    BioStock: BrainCool and KI conduct major cardiac arrest study

    BrainCool will deliver its products RhinoChill and BrainCool System to Karolinska Institutet for a large international clinical study pre-hospital cooling of cardiac arrest patients. In a comment to BioStock, CEO Martin Waleij says that the deal value of 3 million SEK is secondary to the fact that RhinoChill can become central in the future treatment of cardiac arrest.Read the full interview with Martin Waleij at biostock.se: https://www.biostock.se/en/2023/03/braincool-and-ki-conduct-major-cardiac-arrest-study/ This is a press release from BioStock - Connecting Innovation & Capital.

    BioStock: BrainCool wants to reform stroke care

    After attracting a lot of attention for its EU-funded stroke study, BrainCool has now launched a new strategy to target stroke as a new medical indication for RhinoChill. In an interview with BioStock, CEO Martin Waleij says that it would mean a paradigm shift for stroke care.Read the full interview with Martin Waleij at biostock.se: https://www.biostock.se/en/2023/03/braincool-wants-to-reform-stroke-care/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

    BrainCool AB (publ): BrainCool has obtained CB certificate for a new generation of RhinoChill® System

    BrainCool AB (publ) has received a CB-certificate from NEMKO for a new generation of RhinoChill® System. The development of RhinoChill has taken place within the framework of the EU project for cooling treatment of stroke patients treated by thrombectomy which started in autumn 2020. The CB certificate is the summary certificate for several test reports and certificates regarding the safety of EMC (electromagnetic compatibility) and various safety tests. The basis available for a CE-marked product is usually not sufficient for access to markets outside the EU/EFTA. As a rule, additional

    BioStock: BrainCool’s CEO on the listing announcement from Nasdaq

    BrainCool has received conditional approval for admission to trading on the Nasdaq First North Growth Market. Talking to BioStock, CEO Martin Waleij says that only formalities remain for the list change to be carried out according to plan at the end of March 2023.Read the full interview with Martin Waleij at biostock.se: https://www.biostock.se/en/2023/03/braincools-ceo-on-the-listing-announcement-from-nasdaq/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

    BioStock: BrainCool on the benefits of uplisting to Nasdaq First North

    Medtech company BrainCool has long aspired to changing marketplace from Spotlight Stock Market to Nasdaq First North. The move would help attract institutional capital, among other key benefits. BioStock got in touch with BrainCool’s CEO Martin Waleij to discuss a list transfer, which he hopes can take place this quarter.Read the interview with Martin Waleij at biostock.se: https://www.biostock.se/en/2023/02/braincool-on-the-benefits-of-uplisting-to-nasdaq-first-north/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

    BioStock: BrainCool’s CEO on FDA approval of Cooral

    BrainCool has reached an important milestone in its oncology project with the product Cooral System. The company has now received market approval from the US Food and Drug Administration for counteracting chemotherapy-induced oral mucositis, a common and serious side effect of cancer treatment. BioStock contacted BrainCool’s CEO Martin Waleij for a comment on the significance of the FDA’s announcement.Read the full interview with Martin Waleij at biostock.se: https://www.biostock.se/en/2022/10/braincools-ceo-on-fda-approval-of-cooral/ This is a press release from BioStock - Connecting

    BioStock: BrainCool’s thrombectomy data presented at NeuroRad 2022

    Earlier this year, BrainCool communicated safety and feasibility data from a clinical study on early brain cooling of 22 stroke patients treated with thrombectomy using the company’s products RhinoChill and BrainCool System. Last week, the EU-funded study Cottis 1 was presented at the scientific meeting NeuroRad 2022 in Germany after a three-month survival follow-up, the standard measure in stroke studies. According to BrainCool’s CEO Martin Waleij, the results are a strong signal that the technology is working, and the next step in the EU-funded project will now be a randomised pivotal

    BrainCool AB (publ) – last exercise period for BrainCool’s warrants, BRAIN TO 2, 2018-2021, September 17 – October 1, 2021

    As part of our agreement with L1 Capital, BrainCool has distributed free warrants to the company's shareholders to reduce dilution. During the period of September 17 – October 1, 2021, holders of BRAIN TO 2 warrants can exercise the warrants and subscribe for new shares. One (1) BRAIN TO 2 warrant can be exchanged for one (1) share, at a price of 2,77 SEK. Note that warrants in serie TO 2 that isn´t sold latest 29 September 2021 alternatively used 1 October is due without any value. Holders of warrants who have their warrants nominee registered in the custody of a bank or broker shall

    New Clinical Study in Japan Shows Statistically  Significant Result in-hospital Rapid Induction of Cooling After Witnessed Shockable Out-Of-Hospital Cardiac Arrest

    A new publication in Circulation Journal, https://pubmed.ncbi.nlm.nih.gov/34261843/[1], with statistically significant results on patients whose collapse to return of spontaneous circulation (ROSC) interval was delayed over 18 min after shockable out-of-hospital cardiac arrest (OHCA) with in-hospital rapid cooling by intravenous ice-cold fluids. The study was an analysis of collected data from 248 comatose survivors with ROSC who were treated with therapeutic hypothermia (34°C for 12–72 h) after witnessed shockable OHCA in Japan. A scientific presentation from Japan, investigating

    BrainCool AB (publ) – The last exercise period for BrainCool’s warrants, BRAIN TO 1, 2017-2020, starts on Friday, November 20, 2020

    As part of BrainCool´s with L1 Capital, BrainCool has distributed free warrants to the company's shareholders to reduce dilution. During the period of November 20 to December 4, 2020, holders of BRAIN TO 1 warrants can exercise the warrants and subscribe for new shares. One (1) BRAIN TO 1 warrant can be exchanged for one (1) share, at a price of 2,77 SEK. After the end of this exercise period, the warrants of series BRAIN TO 1 expire and the holders lose their right to subscribe for shares. Holders of warrants who have their warrants nominee registered in the custody of a bank or broker

    New 2020 AHA Guidelines recommend implementation of cooling as early as possible and advanced cooling systems.

    The AHA science experts review the new evidence and update the AHA’s guidelines for cardiopulmonary resuscitation (CPR) and emergency cardiovascular care (ECC) have confirmed and reinforced implementation of TTM as soon as possible and the strongly advocating the use of high quality TTM Systems (with a feedback loop) Enclosed documents • Enclosed the Highlights from the 2020 American Heart Association Guidelines for CPR and ECC.pdf ( note, slide 9 and 10 ). https://cpr.heart.org/-/media/cpr-files/cpr-guidelines-files/highlights/hghlghts_2020_ecc_guidelines.pdf • Top 10 Take-Home

    BrainCool AB (publ) - Exercise period for BrainCool’s warrants, BRAIN TO 2, 2018-2021, September, 18 – October, 2, 2020

    As part of our agreement with L1 Capital, BrainCool has distributed free warrants to the company's shareholders to reduce dilution. During the period of September 18 – October 2, 2020, holders of BRAIN TO 2 warrants can exercise the warrants and subscribe for new shares. One (1) BRAIN TO 2 warrant can be exchanged for one (1) share, at a price of 2,77 SEK. Holders of warrants who have their warrants nominee registered in the custody of a bank or broker shall contact their bank to exercise the warrants for subscription. For directly registered warrant holders, subscription shall be

    BrainCool AB (publ) - Exercise period for BrainCool’s warrants, BRAIN TO 3, 2019-2022, August 24 – September 7, 2020

    As part of our agreement with L1 Capital, BrainCool has distributed free warrants to the company's shareholders to reduce dilution. During the period of August 24 to September 7, 2020, holders of BRAIN TO 3 warrants can exercise the warrants and subscribe for new shares. One (1) BRAIN TO 3 warrant can be exchanged for one (1) share, at a price of 2,77 SEK. Holders of warrants who have their warrants nominee registered in the custody of a bank or broker shall contact their bank to exercise the warrants for subscription. For directly registered warrant holders, subscription shall be

    BrainCool AB (publ): Change in terms and conditions in warrants of series TO1, TO2 and TO3

    On April 8, 2020, BrainCool announced that the company is conducting a directed rights issue comprising 1,550,000 shares at a price of SEK 2,77 per share. As a result of the new shares being registered with Bolagsverket, there was a change in the terms of the warrants of series TO1, TO2 and TO3, as stated in §8 section 1.1 clause 11 of the terms. The change covers the strike price for all three series that now amounts to SEK 2,77. Otherwise, there are no changes in the terms and conditions. The conversion prices for the three series previously amounted to: TO1    5,50 SEK TO2    5,50

    BrainCool AB (publ) - market clearance in Europe for Cooral® Systems to prevent Oral Mukosit

    BrainCool AB (publ) CE-marks Cooral® Systems, which means that market clearance for ehe European market is now in place, to prevent oral mucositis (OM). OM is a serious side effect that can arise from radiation and chemotherapy treatment of various cancers. The approval for the Cooral® System is as an invasive product, which paves the way for a market launch as clinical data is now submitted for presentation at the ESMO conference on 18-22 September (European Society for Medical Oncology, reference 1). Cooral® Systems has been assessed in a Nordic clinical trial on a total of 180

    New Scientific Publication with Rhinochill System in One of The Most Prestigious High Rank Medical Journal (The Intensive care medicine journal)

    The publication, published online today , titled "Time to intra-arrest therapeutic hypothermia in out-of-hospital cardiac arrest patients and its association with neurologic outcome: a propensity matched sub-analysis of the PRINCESS trial" is to be part of the coming June issue of the prestigious Journal of Intensive Care Medicine (impact factor 18.97 in 2018). Intensive Care Medicine is a monthly peer reviewed medical journal covering intensive care or critical care and emergency medicine. The publication authored by the research group of the PRINCESS trial (Dr. Per Nordberg et al) and two

    BrainCool and The R Adams Cowley Shock Trauma Center (“Shock Trauma”) at University of Maryland have received a grant of USD 100,000 for the project “IQool Fever Prevention in the Neuro-ICU”

    The US temperature management market is divided into two patient types, cardiac care and neurocritical care. Shock Trauma, one of the largest trauma centers in the US is currently evaluating the IQool™ System for purchase for the patient type neurocritical care. IQool™ has several unique features using an intelligent, safe and simple method. In addition, two other major trauma centers on the east coast are currently evaluating IQool™, and BrainCool will host a satellite symposium in New York City in April, where data of the device is to be presented. Aside from the above sales

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe

    Media